Open Access Open Access  Restricted Access Subscription Access

A STUDY OF OCCURRENCE OF DRUG DEFAULTERS AND EVALUATION OF SAFETY PROFILE AMONG ANTI TUBERCULAR DRUGS

M. K. Vijayalaxmi, Dheeraj Alexander, Natasha J. Nambiar

Abstract


Objective: To assess the frequency of drug defaulters among patients on anti tubercular treatment along with the occurrence of drug related adverse effects.

Methodology: Patients (n=35) diagnosed with tuberculosis and undergoing treatment under Directly observed treatment short course (DOTS) were enrolled based on specific inclusion and exclusion criteria. Details of medical history and relevant investigations were filled out in a proforma sheet and revised at the end of 1st, 2nd and 3rd month of follow-up treatment. Data was analyzed by chi square test and fishers test.

Results: Important factors for patient non compliance in the present study were adverse drug reactions and symptomatic improvement in patient’s health. Majority of the defaulters were males and 80% were in the age group 35-54 years. The adverse drug reactions encountered were pruritus (17.1%), nausea (11.4%) and vomiting (8.6%) and joint pain (2.9%).The study revealed that 69.2% of the patients developed adverse effects during the 1st month of treatment.

Conclusion: Although not significant the present study attempts to study the adverse effects of anti tubercular drugs and the reasons behind patient non compliance. Defaulting is a major obstacle in the cure of tuberculosis and efforts to narrow this subset must be made to increase adherence to drug treatment and curtail the emergence of drug resistant strains.


Keywords


Anti tubercular drugs, Patient compliance, Adverse drug reaction, Drug defaulters, Drugs, Anti tubercular treatment

Full Text:

PDF

References


World Health Organization. Global Tuberculosis Control. (2001). WHO report, Geneva, Switzerland: WHO/CDS/TB, p.287.

Kopanoff DE, Snider DE, and Caras GJ. (1978). “Isoniazid related hepatitis”, Am rev respire dis, Vol.117, pp.991-1001.

Burman WJ, and Reeves RR. (2001). “Hepatotoxicity from rifampin plus pyrazinamide. Lessons for policymakers and messages for care providers”, Am J Respir Crit Care Med, Vol.164, pp.1112-1113.

Ganapathy S., Chandrasekaran V, Britto JJ, Jemima SF, Charles N, Santha T, Sudarsanam NM, and Prabhakar R. (1994). “A study of patients ‘Lost‘ from short course chemotherapy under the district tuberculosis programme in South India”, Lung India, Vol.12(3), pp.129-134.

Globe M, Isheman MD, Madsen LA, et al. (1993). “Treatment of 171 patients with pulmonary tuberculosis resistance to Isoniazid and Rifampicin”, N England J Med, Vol.328, pp.527-532.

WHO-WHO/IUATLD Global project on Anti-tuberculosis drug resistance surveillance: Anti-tuberculosis drug resistance in World, report no 2, Geneva: WHO 2000WHO/CDC/TB/2000, p.278.

Ramasivan CN. (1998). “An overview of drug resistance tuberculosis in India”, Ind J Tuber, Vol.45, pp.73-81.

Managing RNTCP programme in your area-A training course manual, (1998), Central TB Divison, DGHS, Ministry of Health and Family Welfare, Nirman Bhavan, New Delhi.

Koju D., Rao B.S., Sreshtha B., Shakya R., et al. (2005). ”Occurence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment”, Kathmandu university journal of science, engineering and technology, September, Vol.1(1).

Pio A, and Chanlet P. (1998). “TB control”, Tuberculosis Handbook, World Health Organization, First Edition, pp.9-54.

Chauhan LS. (2004). “Status report on DOTS expansion and implementation during the 4th quarter 2003”, J Indian Med Assoc, Vol.102, pp.256-281.

Rafei UM. (1998), “50 Years: Commemorative series 4;Tuberculosis in the south east Asia region”, World Health Organization.Vol.1, pp.1-12.

Revised National Tuberculosis Control Programme. (1997). “Technical guidelines for TB control”, Central TB Division. Directorate General of Health Services, Nirman Bhavan, New Delhi, India 1997.

Pandit N., Choudhary S.K. (2006). “Study of Treatment Compliance in Directly observed Therapy for Tuberculosis”, Indian Journal of Community Medicine, Vol.31(4).

Jakubowiak W, Bogorodskaya E, Borisov S, Danilova I, Kourbatova E. (2009). “Treatmnent interruptions and duration associated with default among new patients with tuberculosis in six regions of Russia”, Int J Infect Dis, Vol.13(3), pp.362-368.

WAA Tissera. (2003). “Non compliance with anti-tuberculosis treatment: at Colombo chest clinic”, NTI bulletin Vol.39, pp.1-9.

Ashry Gad, et al. (1997). “Compliance With Anti Tuberculosis Drugs Among Tuberculosis Patients In Alexandria,Egypt”, Vol.3(2), pp.244-250.

Johansson E, Diwan VK, Huong ND, and Ahlberg BM. (1996). Staff And Patient Attitudes To Tuberculosis And Compliance With Treatment:An Exploratory Study In A District In Vietnam”, Tuber Lung Dis., Vol.77(2), pp.178-183.

Al-Hajjaj Ms, and Al-Khatim IM, (2000). “High Rate Of Non Compliance With Anti Tuberculosis Treatment Despite A Retrieval System: A Call For Implementation Of Directly Observed Therapy In Saudi Arabia”, Int J Tuberc Lung Dis, Vol.4, pp.345-349.

Yee D, Valiquette C, Pelletier M, Parisien I, Rocheri, and Menezies D. (2003). “Incidence Of Serious Side Effects From First Line Anti-Tuberculosis Drugs Among Patients Treated For Active Tuberculosis”, Am J Respir Crit Care Med, Vol.167, pp.1472-1477.

Tekle B, Mariam DH, and Ali A. (2002). “Defaulting From Dots And Its Determinants In Three Districts Of Arsi Zone In Ethiopia”, Int J Tuberc Lung Dis. Vol.6(7), pp.573-579¬¬.


Refbacks

  • There are currently no refbacks.


Send mail to ijmpr@ijmpr.com with questions or comments about this web site. 

International Journal of Medical and Pharma Research, All rights reserved.